Achieving Unique Synergies In Antibody Expression

Source: Catalent

By Rachel Kravitz, Wendy Vredenburgh, Victoria Chrostowski and Greg Bleck

Antibody Expression

Shortening timelines to generate more productive, stable and high expressing cell lines is the goal of any cell line development program. View the technical poster to learn how combining Catalent’s GPEx® cell line development technology with Berkeley Lights, Inc.’s Beacon® platform for clonal cell line selection resulted in stable, higher-expressing clones in a shortened time frame.

CHO pooled cell lines producing two different antibodies were developed using GPEx® technology. Antibody 1 was identified as easier to express and Antibody 2 was more difficult to express. Clonal cell lines were isolated from both pools using two different methodologies. The first method consisted of two consecutive cycles of cloning using the ClonePixTM system. The second method consisted of one cycle, using the Beacon® system. Beacon® system top clones on average were 1.5-fold higher for Antibody 1 and 3-fold higher for Antibody 2. Unoptimized clonal titers ranged up to 6.8 g/L for Antibody 1 and 2.8 g/L for Antibody 2. Detailed methodologies and clonal variation will be highlighted.

access the Poster!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Outsourced Pharma